The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

ACT

Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam

January 17, 2017 - 15:36 -- Open Access
Author(s): 
Ngo Viet Thanh, Nguyen Thuy-Nhien, Tran Tinh Hien, et al.
Reference: 
Malaria Journal 2017 16:27, 13 January 2017

Alternative treatments are urgently needed.

Medical Condition: 
Medical Treatment: 

Report: Independent Evaluation of the Phase 1 of the Affordable Medicines Facility - malaria (AMFm), Multi-Country Evaluation Report: Final Report

October 8, 2012 - 13:30 -- Ingeborg van Schayk
Author(s): 
The Global Fund to Fight AIDS, Tuberculosis and Malaria
Reference: 
AMFm Independent Evaluation Team (2012).

The goal of AMFm is to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment. The AMFm pilot phase was launched in April 2009 and began operations in July 2010. It set out to increase availability, particularly through private outlets where most people seek their treatments, and drive down the price of ACTs through a factory-gate global subsidy of ACTs combined with country-level measures to support its implementation.

Product: 
Company: 
Medical Condition: 
Medical Treatment: 

Effects of malaria volunteer training on coverage and timeliness of diagnosis: a cluster randomized controlled trial in Myanmar

September 7, 2012 - 07:30 -- Kabogo Ndegwa
Author(s): 
Ohnmar -, Tun-Min -, San-Shwe -, Than-Win -, Chongsuvivatwong V
Reference: 
Malaria Journal 2012, 11:309 (4 September 2012)

MalariaWorldThe results show that implementing volunteer programmes to improve the coverage of accurate and timely diagnosis with RDT and early treatment may be beneficial but the timeliness of detection and sustainability must be improved.

Medical Condition: 

Delayed Plasmodium falciparum clearance following artesunate-mefloquine combination therapy in Thailand, 1997-2007

August 30, 2012 - 07:58 -- Kabogo Ndegwa
Author(s): 
Vijaykadga S, Alker AP, Satimai W, MacArthur JR, Meshnick SR, Wongsrichanalai C
Reference: 
Malaria Journal 2012, 11:296 (28 August 2012)

MalariaWorldDelayed resolution of parasitaemia after AM treatment increased in eastern Thailand between 1997 and 2007, which may be an early manifestation of decreased artesunate susceptibility.

Country: 
Medical Condition: 
Medical Treatment: 

NOT Open Access | Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy

August 15, 2012 - 09:17 -- Kabogo Ndegwa
Author(s): 
Makoah N. Aminake, Aman Mahajan, Kelly Chibale, et al.
Reference: 
Bioorganic & Medicinal Chemistry, Volume 20, Issue 17, 1 September 2012, Pages 5277–5289

MalariaWorldMalaria and HIV are among the most important global health problems of our time and together are responsible for approximately 3 million deaths annually.

Medical Condition: 
Medical Treatment: 

NOT Open Access | Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands

June 26, 2012 - 08:49 -- Kabogo Ndegwa
Author(s): 
I. Cavaco, R. Piedade, M. I. Msellem, A. Bjorkman and J. P. Gil
Reference: 
Tropical Medicine & International Health, Volume 17, Issue 7, pages 854–857, July 2012

MalariaWorldAmodiaquine (AQ) is a 4-aminoquinoline widely used in the treatment of malaria as part of the artemisinin combination therapy (ACT).

Country: 
Medical Condition: 
Medical Treatment: 

Quality of anti-malarials collected in the private and informal sectors in Guyana and Suriname

June 20, 2012 - 12:45 -- Kabogo Ndegwa
Author(s): 
Evans L, Coignez V, Barajos A, Bempong D, Bradby S, Dijiba Y, James M, Bretas G, Adhin M, Ceron N, Hinds-Semple A, Chibwe K, Lukulay P, Pribluda V
Reference: 
Malaria Journal 2012, 11:203 (15 June 2012)

http://www.malariajournal.com/content/pdf/1475-2875-11-203.pdfThe findings of the studies in both countries point to significant problems with the quality of anti-malarial medicines available in private and informal sector facilities as well as the availability of therapy not compliant with national treatment guidelines.

Country: 
Medical Condition: 
Medical Treatment: 

Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal

June 20, 2012 - 08:59 -- Kabogo Ndegwa
Author(s): 
Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B
Reference: 
Malaria Journal 2012, 11:197 (13 June 2012)

MalariaWorldSince 2004, the prevalence of chloroquine resistance had decreased.

Country: 
City: 
Medical Treatment: 

In Vitro Sensitivity of Plasmodium falciparum from China-Myanmar Border Area to Major ACT Drugs and Polymorphisms in Potential Target Genes

June 14, 2012 - 07:59 -- Kabogo Ndegwa
Author(s): 
Zenglei Wang, Daniel Parker, Zhaoqing Yang, et al.
Reference: 
PLoS ONE 7(5): e30927

MalariaWorldDrug resistance has always been one of the most important impediments to global malaria control.

Country: 
Medical Condition: 

Open Access | Multiple treatment comparisons in a series of anti-malarials trials with an ordinal primary outcome and repeated treatment evaluations

May 9, 2012 - 11:00 -- Kabogo Ndegwa
Author(s): 
Whegang Youdom S, Samson A, Basco LK, Thalabard J
Reference: 
Malaria Journal 2012, 11:147 (3 May 2012)

MalariaWorldBayesian mixed treatment comparisons of a network of connected randomized trials with repeated measurements of the primary categorical outcome allowed to take into account both the individual- and between- studies sources of heterogeneity.

Organization: 
Medical Condition: 

Pages

Subscribe to RSS - ACT